MSFT
Microsoft Corporation
MSFT's fundamentals are strong and it looks cheap: trading at 27x earnings, below its usual 34x. Analysts expect strong earnings growth.
RCT
RedCloud Holdings plc
There isn't enough reported data to score RCT yet.
MSFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
MSFT's revenue, profitability, cash flow and balance sheet are all currently healthy.
RCT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RCT's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
MSFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $523 | — |
| Cheap | 27x | $525 | +0.4% |
| Current | 27x | $523 | — |
| Fair | 34x | $652 | +25% |
| Expensive | 37x | $711 | +36% |
Historical ranges are pointers, not guarantees.
MSFT's PE is in its cheap range at 27x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
RCT PE Valuation
RCT has no meaningful PE right now: it lost money over the past year.
MSFT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for MSFT, with profitability holding steady.
RCT Forward outlook
There aren't enough analyst estimates for RCT to show an outlook.
MSFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $20.79 | +8.6% |
| Q3 2026 | $19.15 | +36% |
| Q2 2026 | $17.95 | +32% |
| Q1 2026 | $16.80 | +30% |
| Q4 2025 | $15.99 | +29% |
| Q3 2025 | $14.06 | +16% |
| Q2 2025 | $13.64 | +16% |
| Q1 2025 | $12.93 | +12% |
| Q4 2024 | $12.41 | +12% |
MSFT's earnings per share have climbed steadily: $19.15 over the past year, up 36% from the year before, and higher year over year for 14 quarters in a row.
RCT Earnings Per Share
RCT and MSFT do not have enough comparable growth data to identify a winner.
MSFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.3B | +19% |
| Q2 2026 | $90B | +18% |
| Q1 2026 | $82.9B | +18% |
| Q4 2025 | $81.3B | +17% |
| Q3 2025 | $77.7B | +18% |
| Q2 2025 | $76.4B | +18% |
| Q1 2025 | $70.1B | +13% |
| Q4 2024 | $69.6B | +12% |
MSFT's revenue has grown year over year every quarter since late 2020: $92.3B last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 50% | +0.9 points |
| Q2 2026 | 45% | +0.2 points |
| Q1 2026 | 46% | +0.7 points |
| Q4 2025 | 47% | +1.6 points |
| Q3 2025 | 49% | +2.3 points |
| Q2 2025 | 45% | +1.8 points |
| Q1 2025 | 46% | +1.1 points |
| Q4 2024 | 45% | +1.9 points |
MSFT has the edge over RCT on profitability, with a higher operating margin.
RCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $24M | +34% |
| Q4 2025 | $30.6M | +101% |
| Q2 2025 | $18M | +124% |
| Q4 2024 | $15.2M | +123% |
| Q2 2024 | $8M | +160% |
RCT has the edge over MSFT in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -71% | +32 points |
| Q4 2025 | -77% | +8.1 points |
| Q2 2025 | -111% | +116 points |
| Q4 2024 | -73% | N/A |
| Q2 2024 | -103% | N/A |
| Q4 2023 | -85% | N/A |
| Q2 2023 | -227% | N/A |
RCT's operating margin was −71% last quarter, up 32 points from the same quarter a year ago.
MSFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.6B | -27% |
| Q2 2026 | $19.6B | -23% |
| Q1 2026 | $15.8B | -22% |
| Q4 2025 | $5.9B | -9.3% |
| Q3 2025 | $25.7B | +33% |
| Q2 2025 | $25.6B | +9.6% |
| Q1 2025 | $20.3B | -3.2% |
| Q4 2024 | $6.5B | -29% |
MSFT's free cash flow has been positive every quarter for seven years: $60B over the past year, down 23% from the year before.
RCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$8.2M | +$7.8M |
| Q4 2025 | -$21.1M | -$1.4M |
| Q2 2025 | -$16M | +$3.7M |
| Q4 2024 | -$19.6M | -$5.4M |
| Q2 2024 | -$19.7M | -$4.6M |
RCT and MSFT do not have enough comparable growth data to identify a winner.
MSFT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -7M shares |
| 1 year | -0.3% | -20M shares |
| 3 years | -0.2% | -16M shares |
| 5 years | -1.6% | -121M shares |
| Available history | -3.2% | -245M shares |
MSFT has the edge over RCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.4B |
| Q2 2026 | $4.6B |
| Q1 2026 | $4.6B |
| Q4 2025 | $7.4B |
| Q3 2025 | $5.7B |
| Q2 2025 | $4.5B |
| Q1 2025 | $4.8B |
| Q4 2024 | $5B |
MSFT spent $21B buying back its own shares over the past year, up 5.2% from the year before.
RCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +55% | +19.6M shares |
| 1 year | +221% | +38.1M shares |
RCT has 55M diluted shares, up 221% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q2 2023 | — |
MSFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.1x | Very low |
MSFT's net debt is less than a year of its operating earnings (EBITDA).
RCT Net Leverage
RCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MSFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.1 | Neutral |
| Stochastic | 68.0 | Neutral |
MSFT's weekly RSI is 62 (neutral) and its Stochastic is 68 (neutral).
RCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 4.3 | Oversold |
RCT's weekly RSI is 23 (oversold) and its Stochastic is 4 (oversold).
MSFT PE vs Technology Sector
| Metric | MSFT | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 28x | 2% below |
| PE % | 16 | 35 | 19 pts below |
MSFT is trading at 27x earnings, in line with the Technology sector's median of 28x.
RCT PE vs Technology Sector
RCT has no meaningful PE right now: it lost money over the past year.
MSFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $524.7 | 0.3% below |
| 20 week MA | $484.8 | 7.9% above |
| 50 week MA | $446.9 | 17% above |
| 100 week MA | $453.8 | 15% above |
| 200 week MA | $411.5 | 27% above |
MSFT has stronger trend alignment. MSFT is above 4 of 5 weekly averages versus RCT above 0 of 3.
RCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.10 | 70% below |
| 20 week MA | $0.17 | 82% below |
| 50 week MA | $0.63 | 95% below |
RCT is in a downtrend: it's below all three of its weekly moving averages, and 95% below its 50-week average.
MSFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $159.0 | $222.8 | +40% |
| 2021 | $222.8 | $334.7 | +50% |
| 2022 | $334.7 | $238.7 | -29% |
| 2023 | $238.7 | $376.0 | +58% |
| 2024 | $376.0 | $430.5 | +14% |
| 2025 | $430.5 | $487.7 | +13% |
| 2026 YTD | $487.7 | $523.0 | +7.2% |
MSFT has the edge over RCT on returns for 2026, with the stronger performance.
RCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $4.50 | $1.44 | -68% |
| 2026 YTD | $1.44 | $0.03 | -98% |
RCT has finished every year since 2025 lower, and it's down 98% so far in 2026.